BRUSSELS, Oct 12 (Reuters) - EU antitrust regulators have resumed their scrutiny of U.S. life sciences company Illumina's (ILMN.O) bid for Grail Inc (GRAL.O) after a two-month temporary halt and will decide by Feb. 4 whether to clear the deal, a European Commission filing showed on Tuesday.
The EU competition enforcer paused its investigation on Aug. 11 while waiting for Illumina to provide requested data. read more
It restarted the clock on Oct. 7. Last month it sent a statement of objections to Illumina for closing the deal before securing regulatory clearance, warning of interim measures. read more
Illumina finalised the deal in August and said it would hold Grail as a separate company while waiting for the EU green light.
Register now for FREE unlimited access to Reuters.com
Our Standards: The Thomson Reuters Trust Principles.